Stryker (SYK) Projected to Post Quarterly Earnings on Thursday

Stryker (NYSE:SYK) is anticipated to issue its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $3.49 per share and revenue of $6.5793 billion for the quarter. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the business earned $2.84 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Stryker to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Stryker Stock Up 2.9%

Shares of NYSE SYK opened at $346.59 on Wednesday. The firm has a fifty day simple moving average of $315.76 and a two-hundred day simple moving average of $335.22. Stryker has a 12 month low of $281.00 and a 12 month high of $403.92. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $132.87 billion, a PE ratio of 40.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.77.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Barclays lowered their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Truist Financial reiterated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Finally, Needham & Company LLC dropped their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $393.39.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC raised its holdings in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP increased its position in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new stake in shares of Stryker during the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC purchased a new position in Stryker in the 2nd quarter worth approximately $253,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.